Dr Roy of Powell Group appeals to start Vivekananda Study Circle in the Universities and Colleges

Dr Roy of Powell Group appeals to start Vivekananda Study Circle in the Universities and Colleges

June 3: Department of Pharmaceutical Technology, Brainware University in collaboration with Association of Pharmaceutical Teachers of India and Indian Association of Pharmaceutical Scientists & Technologists organised a two day National Conference on Current Scenario and Challenges in Pharmaceutical Sciences and Research. Hon’ble Chancellor of the host University Mr Phalguni Mukhopadhyay felicitated Dr Sudipta Narayan Roy of Powell Group, who is currently the Chairman of ASSOCHAM National Ayush Task Force. Other renowned Kolkata based Pharmaceutical Industry leaders like Mr Ranajit Dey of Dey’s Medical and Debarshi Duttagupta of East India Pharmaceuticals were also felicitated in the function.

In the Industry Academia interaction, Dr Roy reminded the Teachers and the Faculty members that they have a vital role in contributing to the National ambition of 5 Trillion dollar economy by grooming the future Pharmaceutical professionals, since India is already known as ‘the pharmacy of the world’.

He appealed to the University representatives and Academicians from different states participating in the conference to start Vivekananda Study Circle in their respective organisations to promote all round development of the students as part of Nation building. He further explained the necessity of ethics and value education through teachings of Swami Vivekananda and its role in inclusive nationalism and economics.

Dr Roy is an alumnus of Purulia Ramakrishna Mission and he shared how Vivekananda’s ideology shaped his entrepreneurial journey. His company Powell Laboratories (P) Ltd. features as one of the top 10 Homoepathy companies in India and has secured a strong presence in the Indian Homoeopathy market which is still dominated by the European multinationals. Dr Roy is featured in ‘Top 10 IIM Ahmedabad alumni Business leader of 2022’ in the CEO Insights magazine.